2020年12月10日 · FOSTER CITY, Calif. & BAD HOMBURG, Germany-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), today announced that the companies have entered into a definitive agreement pur...

2021年3月4日 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration.

2020年12月10日 · MYR GmbH is a private, commercial stage biotechnology company headquartered in Bad Homburg, Germany. The company is dedicated to the development of Bulevirtide; Bulevirtide is a first-in-class entry inhibitor which binds to the NTCP receptor for HDV and other indications. MYR started operations in 2011 and has been supported by its founders ...

MYR is a biotechnology company developing and commercilizing therapeutics for the treatment of chronic hepatitis B and D infections. View contacts for MYR GmbH to access new leads and connect with decision-makers.

2020年12月10日 · FOSTER CITY, Calif. & BAD HOMBURG, Germany-- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of...

MYR is the first private German biotech company to successfully take a drug from preclinical development to market. MYR’s lead compound ‘Bulevirtide’, sold under the brand name HepcludexTM, is a first-in-class entry inhibitor for the treatment of the most severe form of viral hepatitis, chronic hepatitis D (HDV).

2020年12月10日 · Under the terms of the sale and purchase agreement, Gilead will acquire MYR for approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential future milestone ...

2020年12月10日 · Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), today announced that the companies have entered into a definitive agreement pursuant to which …

MYR Pharmaceuticals is a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B (HBV) and D (HDV) infections. The company’s lead compound bulevirtide (Myrcludex) is a first-in-class entry inhibitor for treatment of chronic HVB and HDV and is currently in a Phase 3 ...

2020年12月12日 · FOSTER CITY, Calif. and BAD HOMBURG, Germany — Gilead Sciences, Inc. and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), announced that the companies have entered into a definitive agreement pursuant to which Gilead will …